Mindsense has opened new avenues of technological approaches to enhance its research activities and support its strategy. Mindsense mission and strategy is based on the huge market opportunity that the discovery of biomarkers for mental disorders is offering. Tremendous suffering and cost associated with mental disorders could be avoided by timely diagnosis, monitoring and treatment of the large impacted population. Mindsense approach will add objectivity to the current process, shorten its duration and allow reliable comparison of clinical status over extended periods of time. The Mindsense concept will provide the psychiatrist and the general practitioner with a blood test to be used as an auxiliary tool for the diagnosis and monitoring of a patient's condition as part of a comprehensive scheme of medical treatments.
Depression is the most prevalent disorder known to date.
There is a growing awareness of psychiatric disorders in the western world. The antidepressant drug market has rapidly developed in the recent years to become one of the largest worldwide. Mindsense approach will significantly improve the choice and management of treatment, its monitoring, the quality of life of the patients and add greater economic value to the medical community.